CL2004000927A1 - Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal. - Google Patents

Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.

Info

Publication number
CL2004000927A1
CL2004000927A1 CL200400927A CL2004000927A CL2004000927A1 CL 2004000927 A1 CL2004000927 A1 CL 2004000927A1 CL 200400927 A CL200400927 A CL 200400927A CL 2004000927 A CL2004000927 A CL 2004000927A CL 2004000927 A1 CL2004000927 A1 CL 2004000927A1
Authority
CL
Chile
Prior art keywords
active agent
dosage form
transdermal dosage
distal surface
distal
Prior art date
Application number
CL200400927A
Other languages
English (en)
Inventor
Reidenberg Stephen A How Bruce
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000927(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of CL2004000927A1 publication Critical patent/CL2004000927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA DE DOSIFICACION TRANSDERMICA QUE COMPRENDE UN AGENTE ACTIVO QUE COMPRENDE UN AGENTE ACTIVO Y UN COMPONENTE DE AGENTE ADVERSO QUE COMPRENDE UN AGENTE ADVERSO, EN LA QUE EL COMPONENTE DE AGENTE ACTIVO DEFINE AL MENOS UN CANAL QUE SE EXTIENDE SUSTANCIALMENTE A TRAVES DE LA MISMA.
CL200400927A 2003-04-30 2004-04-30 Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal. CL2004000927A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46723503P 2003-04-30 2003-04-30
US46724303P 2003-04-30 2003-04-30

Publications (1)

Publication Number Publication Date
CL2004000927A1 true CL2004000927A1 (es) 2005-01-28

Family

ID=33436723

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400927A CL2004000927A1 (es) 2003-04-30 2004-04-30 Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.

Country Status (22)

Country Link
US (1) US8778382B2 (es)
EP (3) EP1641441B1 (es)
JP (1) JP5048324B2 (es)
KR (1) KR101159828B1 (es)
AR (1) AR047936A1 (es)
AU (1) AU2004235794B8 (es)
BR (1) BRPI0409945A (es)
CA (1) CA2522529C (es)
CL (1) CL2004000927A1 (es)
EA (1) EA009623B1 (es)
EC (1) ECSP056191A (es)
IS (1) IS2935B (es)
ME (1) ME00276B (es)
MX (1) MXPA05011703A (es)
MY (1) MY141815A (es)
NO (1) NO332157B1 (es)
NZ (1) NZ542969A (es)
PE (2) PE20050146A1 (es)
RS (1) RS20050812A (es)
TW (1) TWI350186B (es)
UA (1) UA82880C2 (es)
WO (1) WO2004098567A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
HRP20090363T1 (hr) * 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004039570B4 (de) * 2004-08-14 2007-03-01 Lts Lohmann Therapie-Systeme Ag Überwachungssystem zum Sammeln und zur transdermalen Weiterdiffusion von Umweltkontaminantien enthaltender Luft und Verfahren hierzu
JP2008510713A (ja) * 2004-08-20 2008-04-10 スリーエム イノベイティブ プロパティズ カンパニー 半透明保護フィルムを有する経皮薬物送達デバイス
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
TWI419717B (zh) * 2005-06-17 2013-12-21 Altea Therapeutics Corp 滲透傳送系統及其使用方法
JP4704829B2 (ja) * 2005-07-15 2011-06-22 ニプロパッチ株式会社 貼付剤、及び貼付剤包装体
BRPI0619806A2 (pt) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
TW200800223A (en) * 2005-12-21 2008-01-01 Shire Pharmaceuticals Inc Transdermal delivery of meptazinol
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
WO2007095147A2 (en) * 2006-02-13 2007-08-23 Aveva Drug Delivery Systems Adhesive preparation comprising sufentanil and methods of using the same
JP5064391B2 (ja) * 2006-07-14 2012-10-31 久光製薬株式会社 貼付剤
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
JP2010501001A (ja) * 2006-08-14 2010-01-14 シャイア ファーマシューティカルズ インコーポレイテッド メプタジノールの経皮送達
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
EP2552425B1 (en) * 2010-04-02 2016-07-27 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
AU2011252039B2 (en) 2010-05-10 2014-06-12 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
WO2012023030A2 (en) * 2010-08-18 2012-02-23 Purdue Pharma L.P. Vacuum avoiding packaging systems and methods thereof
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2013305563B2 (en) * 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
EA030797B1 (ru) 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения
US10646452B2 (en) 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CN107106552A (zh) * 2014-12-19 2017-08-29 3M创新有限公司 包含芬太尼的透皮药物递送装置
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
GB201513441D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal delivery system
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US20190015352A1 (en) * 2017-07-14 2019-01-17 Pendleton Brewster Wickersham Applicators & Patches for Dermal & Transdermal Treatment Material & Drug Delivery, Methods of Making Them, & Methods of Use
CA3076815A1 (en) * 2017-09-27 2019-04-04 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
WO2020009685A1 (en) * 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
DE102018216244A1 (de) * 2018-09-24 2020-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Barriereschicht
GB2588612A (en) * 2019-10-28 2021-05-05 Univ Of Sunderland Transdermal patch
EP4422607A4 (en) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1602344A (en) 1924-01-09 1926-10-05 Eagle Peter Medicating compress
US2807262A (en) 1952-12-10 1957-09-24 Robert B Lew Perforated plastic adhesive tape bandage
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4539256A (en) 1982-09-09 1985-09-03 Minnesota Mining And Manufacturing Co. Microporous sheet material, method of making and articles made therewith
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
DE3546830C2 (de) 1984-07-23 1995-07-20 Alza Corp Transdermales Abgabesystem zur Verabreichung von Fentanyl
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4687481A (en) * 1984-10-01 1987-08-18 Biotek, Inc. Transdermal drug delivery system
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4960467A (en) 1985-02-11 1990-10-02 The United States Of America As Represented By The Secretary Of The Army Dermal substance collection device
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4693776A (en) 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4954343A (en) 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4917688A (en) 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US4822802A (en) 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
JPH0696529B2 (ja) 1987-03-31 1994-11-30 積水化学工業株式会社 ニトログリセリン貼付剤およびその製造方法
US5186939A (en) 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
US4879297A (en) 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3722775A1 (de) * 1987-07-09 1989-01-19 Lohmann Therapie Syst Lts Transdermales therapeutisches system
US4788064A (en) 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
ES2062093T3 (es) 1988-08-02 1994-12-16 Ciba Geigy Ag Emplasto de varias capas.
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5176917A (en) * 1989-03-15 1993-01-05 Lts Lohmann Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5750136A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5750134A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US5032637A (en) 1990-03-14 1991-07-16 Adhesives Research Inc. Water-inactivatable pressure sensitive adhesive
US5149719A (en) 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
DE4020144A1 (de) 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5382246A (en) * 1990-09-18 1995-01-17 Koyo Disposable Goods Company Disposable diaper
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5981666A (en) 1991-07-12 1999-11-09 Adhesives Research, Inc. Method for the production of a high performance pressure sensitive adhesive
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
US5518734A (en) 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5352516A (en) 1992-01-31 1994-10-04 Adhesives Research, Inc. Water-inactivatable pressure sensitive adhesive
US5756117A (en) 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
US5264219A (en) 1992-08-07 1993-11-23 Minnesota Mining And Manufacturing Company Transdermal drug delivery backing
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5462743A (en) * 1992-10-30 1995-10-31 Medipro Sciences Limited Substance transfer system for topical application
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
CA2173855C (en) 1993-10-29 2007-06-26 Mieczyslaw H. Mazurek Pressure-sensitive adhesives having microstructured surfaces
US5395907A (en) 1993-11-29 1995-03-07 Adhesive Research, Inc. Water-soluble pressure sensitive adhesive
US5508367A (en) 1993-11-29 1996-04-16 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5494680A (en) 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
JPH07206710A (ja) 1994-01-21 1995-08-08 Nitto Denko Corp 経皮投薬用テープ製剤
US5536263A (en) 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
GB9409281D0 (en) * 1994-05-10 1994-06-29 Svedman Paul Transdermal device
US5589480A (en) 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
JP3908795B2 (ja) 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
US6063838A (en) 1995-02-16 2000-05-16 3M Innovative Properties Company Blended pressure-sensitive adhesives
US5573778A (en) 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US6093419A (en) 1995-06-07 2000-07-25 Lectec Corporation Compliance verification method and device in compulsory drug administration
WO1997004835A1 (de) 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5733571A (en) 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
US5703169A (en) 1996-01-24 1997-12-30 Adhesives Research, Inc. Non-corrosive, low volatiles-containing pressure sensitive adhesive
EP0914097B1 (en) 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
US6165499A (en) 1996-03-25 2000-12-26 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
US5783583A (en) 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998017315A2 (en) 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
JP2001503749A (ja) 1996-10-30 2001-03-21 セラテック・インコーポレーテッド 透過促進剤としてのグリコール酸の脂肪酸エステル及びその塩
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19653606A1 (de) 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
DE19653605C2 (de) 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
DE19654468C1 (de) 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
US6239228B1 (en) 1997-02-21 2001-05-29 Adhesives Research, Inc. Pressure sensitive adhesive containing macromer having repeat hydrophilic moieties
US5951999A (en) 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO1998037871A1 (en) 1997-02-28 1998-09-03 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of testosterone
US6018092A (en) 1997-03-04 2000-01-25 3M Innovative Properties Company Medical adhesive bandage, delivery system and method
US5804215A (en) 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US5976547A (en) 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6143278A (en) 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6294038B1 (en) * 1998-08-05 2001-09-25 Advanced Label Systems, Inc. Apparatus and method for applying linerless labels
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6159497A (en) 1998-10-30 2000-12-12 Noven Pharmaceuticals, Inc. Patch applicator
US6129929A (en) 1998-10-30 2000-10-10 Noven Pharmaceuticals, Inc. Patch applicator
US6136807A (en) 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
WO2002054996A2 (en) 2000-10-23 2002-07-18 Euro Celtique Sa Terazosin transdermal device and methods
US7018649B2 (en) 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
DE60141596D1 (de) 2000-10-23 2010-04-29 Euro Celtique Sa Transdermales system zur verabreichung von loratadin und dessen verwendung
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
ATE364380T1 (de) 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
EP2266719B1 (en) 2001-04-23 2016-06-08 Euro-Celtique S.A. Disposal system for transdermal dosage form
SI2062573T1 (sl) * 2001-05-01 2012-02-29 Euro Celtique Sa Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
CA2446738C (en) 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
JP4302991B2 (ja) 2001-05-22 2009-07-29 ユーロ−セルティーク エス．エイ． 経皮性剤形を分配する容器及び装置
EP1395224A4 (en) 2001-05-22 2005-10-26 Euro Celtique INVIOLABLE ORAL DOSAGE FORM
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
JP2005506885A (ja) 2001-10-22 2005-03-10 スリーエム イノベイティブ プロパティズ カンパニー 経皮／経粘膜パッチ包装
JP2005516926A (ja) 2001-12-17 2005-06-09 アリックス セラピューティクス 鎮痛薬の送達システム及び使用方法
US6838078B2 (en) 2002-01-16 2005-01-04 3M Innovative Properties Company Film-forming compositions and methods
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
RU2209062C1 (ru) 2002-03-19 2003-07-27 Институт физиологии им. И.П.Павлова РАН Вещество, обладающее седативным действием
WO2003079945A1 (en) 2002-03-20 2003-10-02 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
EP1513532B1 (en) 2002-06-10 2007-02-28 Euro-Celtique S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
US20050191340A1 (en) 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
AU2003272237B2 (en) * 2002-08-30 2009-11-19 Alza Corporation Embossable and writable multilaminate backing construction
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AU2003297073A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297074A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
US20040202708A1 (en) 2003-04-14 2004-10-14 3M Innovative Properties Company Transdermal drug delivery device with translucent inorganic barrier layer
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20040219195A1 (en) 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219198A1 (en) 2003-05-01 2004-11-04 3M Innovative Properties Company Transdermal drug delivery device with multilayer backing

Also Published As

Publication number Publication date
ME00276B (me) 2011-05-10
EP1641441B1 (en) 2014-03-12
JP2006525370A (ja) 2006-11-09
AU2004235794B2 (en) 2009-06-04
BRPI0409945A (pt) 2006-04-25
UA82880C2 (en) 2008-05-26
NO20054682D0 (no) 2005-10-12
NO20054682L (no) 2005-11-30
CA2522529A1 (en) 2004-11-18
IS2935B (is) 2016-01-15
EP2319505A1 (en) 2011-05-11
AR047936A1 (es) 2006-03-15
JP5048324B2 (ja) 2012-10-17
MXPA05011703A (es) 2006-01-23
WO2004098567A2 (en) 2004-11-18
NO332157B1 (no) 2012-07-09
EP1641441A2 (en) 2006-04-05
PE20081297A1 (es) 2008-09-17
EA009623B1 (ru) 2008-02-28
KR101159828B1 (ko) 2012-07-04
CA2522529C (en) 2015-10-20
EA200501702A1 (ru) 2006-04-28
EP2316440A1 (en) 2011-05-04
IS8060A (is) 2005-10-04
PE20050146A1 (es) 2005-03-26
US8778382B2 (en) 2014-07-15
KR20070088823A (ko) 2007-08-30
US20050002997A1 (en) 2005-01-06
RS20050812A (sr) 2007-12-31
NZ542969A (en) 2009-09-25
AU2004235794B8 (en) 2009-07-23
TW200505509A (en) 2005-02-16
ECSP056191A (es) 2006-04-19
WO2004098567A3 (en) 2005-01-13
MY141815A (en) 2010-06-30
MEP49208A (en) 2011-02-10
TWI350186B (en) 2011-10-11
AU2004235794A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
CL2004000927A1 (es) Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.
AR054227A1 (es) Composicion de principios activos
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
NO20054681L (no) Farmasoytiske produkter
TW200514593A (en) Method and device for enhancing transdermal agent flux
PL2178504T3 (pl) Roztwór oczny na bazie prostagladyn bez środka konserwującego
WO2006006172A3 (en) Use of anti-amyloid agents for treating and typing pathogen infections
AR040302A1 (es) Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
CL2008002279A1 (es) Combinacion farmaceutica que comprende un compuesto heteroarilbiciclico o arilbiciclico y un agente auxiliar; proceso de preparacion; y envase farmaceutico, util en el tratamiento y/o profilaxis de la distrofia muscular de duchenne, distrofia muscular de becker y caquexia.
WO2007018944A3 (en) Gate electrode structures and methods of manufacture
AR060739A1 (es) Composiciones orales que comprenden polimeros de siloxano
CL2007002026A1 (es) Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
BRPI0414114A (pt) uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
ES2325291A1 (es) "uso de un extracto de silybum marianum"
GT200400183A (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
TW200733954A (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
AR039948A1 (es) Metodo mejorado para el tratamiento de queso desmenuzado con un compuesto antihongo de polieno
CR8030A (es) Dosis transdermica resistente a las interferencias, que comprende un componente de agente activo y un componente de agente nocivo en el sitio distal de la capa del agente
ATE399532T1 (de) Medizinische seife
MX2022005321A (es) Dispositivos medicos anticonceptivos.
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer